Late-Breaking Clinical Trials I (Session 102)
Saturday, March 28 ● 9:30 – 10:30 a.m. CT
Main Tent, Great Hall

• Ultrasound-Facilitated Catheter-Directed Thrombolysis Vs Anticoagulation Alone For Acute Intermediate-High-Risk Pulmonary Embolism: Primary Results of the HI-PEITHO Randomized Clinical Trial
• Outcomes in Patients With Atrial Fibrillation Randomized to Receive Left Atrial Appendage Closure or Oral Anticoagulation: Primary Results of the CHAMPION-AF Clinical Trial
• Primary Left Ventricular Unloading in Anterior ST-Segment Elevation Myocardial Infarction (STEMI) Without Cardiogenic Shock: Results From the STEMI-Door to Unload Randomized Clinical Trial

Late-Breaking Clinical Trials II (Session 105)
Saturday, March 28 ● 3:45 – 4:45 p.m. CT
Main Tent, Great Hall

• Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled Hypertension
• Evolocumab in Patients Without Significant Atherosclerosis: Results From VESALIUS-CV
• Intensive Low-Density Lipoprotein Cholesterol Targeting in Patients With Atherosclerotic Cardiovascular Disease
• DASH-Patterned Groceries to Reduce Blood Pressure Among Adults With Treated Hypertension: Results From the GoFreshRx Randomized Clinical Trial

Late-Breaking Clinical Trials III (Session 106)
Sunday, March 29 ● 8:30 – 9:30 a.m. CT
Main Tent, Great Hall

• Controlled Trial of High-Risk Coronary Intervention With Percutaneous Left Ventricular Unloading (CHIP-BCIS3)
• A Large-Scale, Global Randomized Trial of Coronary Physiology Derived From Conventional Angiography Compared With An Invasive Pressure Wire-Based Approach to Guide Percutaneous Coronary Intervention
• A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina- ORBITA-CTO Trial
• Fractional Flow Reserve or 3d-quantitative Coronary Angiography-Based Vessel-Ffr Guided Revascularization – The Fast Iii Trial

Late-Breaking Clinical Trials IV (Session 107)
Sunday, March 29 ● 10:45 – 11:45 a.m. CT
Main Tent, Great Hall

• Spironolactone in the Treatment of Heart Failure
• Efficacy and Safety of Sotatercept in Combined Post- and Pre-Capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction: Results From the Phase 2 Cadence Trial
• Lung Impedance-Guided Therapy in Heart Failure With Preserved Ejection Fraction: Results of a Randomized Clinical Trial
• Mavacamten in Symptomatic Adolescent Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the Phase 3 Scout-HCM Trial

Late-Breaking Clinical Trials V (Session 110)
Sunday, March 29 ● 4 – 5 p.m. CT
Main Tent, Great Hall

• Redo-Surgery Versus Transcatheter Valve-In-Valve For Mitral Bioprosthetic Dysfunction: The SURVIV Trial
• Transcatheter Aortic Valve Implantation Without Routine Percutaneous Coronary Intervention: A Randomized Controlled Trial
• Protect The Head To Head Trial: Randomized Comparison of Emboliner Embolic Protection Catheter Vs. Sentinel Cerebral Protection System During Transcatheter Aortic Valve Replacement
• Two-Year Outcomes After Transcatheter Tricuspid Repair Without Cross-over in the Randomized Tri-fr Trial

Late-Breaking Clinical Trials VI (Session 111)
Monday, March 30 ● 8:30 – 9:30 a.m. CT
Main Tent, Great Hall

• Heartline Study: A Decentralized Randomized Trial of Apple Watch and iPhone-Facilitated AF Detection and Cardiovascular Outcomes in Older Adults Without Known Atrial Fibrillation
• Digoxin in Rheumatic Heart Disease: A Multi-Center, Randomized, Double Blind, Placebo-controlled Trial
• Discontinuation of β-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction
• Effect of Intensive Triglyceride Lowering With Olezarsen on Progression of Coronary Atherosclerosis: A Coronary Cta Substudy of The Essence-TIMI 73b Randomized Trial

Late-Breaking Clinical Trials VII (Session 112)
Monday, March 30 ● 10:45 – 11:45 a.m. CT
Main Tent, Great Hall

• Primary Efficacy and Safety Results From the Phase 3 Sirolimus-Coated Balloon For Infra-inguinal Peripheral Arterial Disease (SirPAD) Trial
• Intravascular Ultrasound Guidance For Complex High-Risk Indicated Procedures – The Ivus Chip Trial
• Intravascular Ultrasound-Guided Versus Angiography-Guided Percutaneous Coronary Intervention In Unprotected Left Main Coronary Artery Disease – The Optimal Trial
• Ivus Or Angiography Guidance For PCI in Complex Coronary Bifurcation Lesions

Featured Clinical Research I (Session 201)
Saturday, March 28 ● Noon – 1 p.m. CT
La Nouvelle B

• A Prospective Multicenter Registry to Define Coronary Vasomotor Disorders in Ischemia With Nonobstructive Coronary Arteries: Primary Results of Discover Inoca
• Impact of Ivabradine on Orthostatic Intolerance, Quality of Life and Heart Rate in Post-Covid Postural Orthostatic Tachycardia Syndrome: Results From the Recover-Autonomic Trial
• Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Sex Differences in Underlying Causes of Myocardial Infarction With No Obstructive Coronary Arteries
• A Sham Controlled Randomised Trial Evaluating the Safety, Acceptability and Efficacy of Autonomic Neuromodulation Using Trans-Cutaneous Vagal Sensory Stimulation in Uncontrolled Hypertensive Patients

Featured Clinical Research II (Session 216)
Saturday, March 28 ● 1:30 – 2:30 p.m. CT
La Nouvelle B

• Effects of Tirzepatide Compared With Dulaglutide on Expanded Cardiorenal Outcomes
• Prevalence and Clinical Impact of Hypercortisolism in Individuals With Resistant Hypertension: Primary Results From the Momentum Study
• Reliability of CAC=0 to Exclude Coronary Plaque in Diverse Global Cohorts: A Global Probability Study of Coronary Artery Disease (GPS-CAD) Analysis
• Community-to-Clinic Linkage Implementation Program to Prevent Hypertension in Barbershops

Featured Clinical Research III (Session 276)
Sunday, March 29 ● 12:15 – 1:15 p.m. CT
La Nouvelle B

• 10-year Follow-up of Clopidogrel Vs Aspirin Monotherapy in Stable Coronary Artery Disease After Percutaneous Coronary Intervention With Drug-eluting Stent
• Coronary CT Derived Fractional Flow Reserve-guided Management of Patients With Stable CAD: 3-year Outcomes From A Multicentre, Pragmatic, Open-label, Randomised Controlled Trial in China
• Role of Screening With Coronary Computed Tomography Angiography in Lipid Management in an Asymptomatic Chinese Population: A Community-Based, Parallel-Group, Open-Label, Randomized Clinical Trial (RESPECT2)
• Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure

Featured Clinical Research IV (Session 291)
Sunday, March 29 ● 1:45 – 2:45 p.m. CT
La Nouvelle B

• Automated Notifications to Improve Referral and Treatment of Severe Aortic Stenosis and Mitral Regurgitation: Outcomes From the Randomized Alert Trial
• A Randomized Controlled Trial of a Novel Just-in-Time Adaptive Mobile Application Intervention to Reduce Sodium Intake and Blood Pressure in Patients With Hypertension
• NOTIFY-HF: A Randomised Pilot Trial of Patient-Facing Heartlogic Alerts in Heart Failure Patients
• MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure): A Randomized Controlled Trial of an Indigenous Food is Medicine Intervention

Featured Clinical Research V (Session 321)
Monday, March 30 ● 8:30 – 9:30 a.m. CT
La Nouvelle B

• Two-Year Outcomes of Transcatheter Tricuspid Valve Replacement For Severe Tricuspid Regurgitation: The TRISCEND II Randomized Trial
• Efficacy and Safety of BHB/HRS-1893 in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From A 12-week Phase 2 Study
• The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-inferiority Randomized Trial
• Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI

Investigative Horizons I (Session 336)
Monday, March 30 ● 10:45 – 11:45 a.m. CT
La Nouvelle B

• Effect of Anti-Fibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden: The Reduce-MFA DZHK 25-trial
• Efficacy and Safety of Enlicitide Decanoate, An Oral Macrocyclic Peptide Inhibitor of PCSK9, Compared With Bempedoic Acid, Ezetimibe, Or Bempedoic Acid Co-Administered With Ezetimibe in Statin-Treated Adults With Hypercholesterolemia: Phase 3 CORALreef AddOn Trial
• Anti-Inflammatory Actions and Safety of the NLRP3 Inhibitor VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
• Prospective Multi-Center Clinical Trial of Artificial-Intelligence Analysis of Retinal Images For Identifying Elevated Atherosclerotic Cardiovascular Risk

Investigative Horizons II (Session 351)
Monday, March 30 ● 12:15 – 1:15 p.m. CT
La Nouvelle B

• Safety and Preliminary Efficacy of AAVrh.10hFXN (LX2006) Gene Therapy in Friedreich Ataxia Cardiomyopathy
• Effect of Financial Support on Quality of Life and Medication Adherence Among Low-Income Patients Following Hospitalization For Heart Failure: The FUND-HF Trial
• Adaptive AI For Cardiovascular Event Adjudication: Identifying Cardiovascular Events Across Changing Definitions in the Odyssey and Euclid Trials
• Artificial Intelligence Based Screening For Structural Heart Disease Using An ECG: Results From the PREVUE-VALVE Study

Investigative Horizons III (Session 366)
Monday, March 30 ● 1:45 – 2:45 p.m. CT
La Nouvelle B

• Artificial Intelligence Model For Evaluating Surgical Techniques of Cardiac Surgeons
• The Npr1 Agonist Xxb750 in Heart Failure
• Safety and Preliminary Efficacy of AAVrh.10hPKP2 (LX2020) Gene Therapy in PKP2- Arrhythmogenic Cardiomyopathy
• Durability of Enlicitide For Lipid Lowering: On-treatment Analysis of Data From CORALreef Lipids and CORALreef HeFH Trials
• Long-Term Survival Benefits and Disease Stabilization With Acoramidis In Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)